Oxford Nanopore Technologies plc Announces Publication: Nanopore IDs >50 Genetic Diseases

Researchers Use Oxford Nanopore Technology To Develop a Single Test Method To Characterise More Than 50 Genetic Diseases

In a Study Published in Science Advances, a Team From the Garvan Institute of Medical Research, Australia, Has Described How Their Method Using Nanopore Sequencing Technology Has the Potential To Reduce the ‘Diagnostic Odyssey' for People With Rare Neurological and Neuromuscular Disease

OXFORD, UK / ACCESSWIRE / March 8, 2022 / A new DNA sequencing based test method developed by a team led by Ira Deveson, Head of Genomics Technologies at the Garvan Institute of Medical Research and collaborators, has been shown to screen for more than 50 genetic neurological and neuromuscular diseases. This new workflow accurately identifies diseases caused by unusually long, repetitive DNA sequences in a person's genes, known as short tandem repeat (STR) expansion disorders. Current genetic screening for these disorders can involve multiple tests, such as muscle or nerve biopsies, and take much longer, sometimes years of investigation to reach an answer.

The STR repeat expansions typically span a longer region of DNA than the read lengths generated by short-read sequencing technology. To overcome this, the research teams used Oxford Nanopore technology, which can read fragments of any length and can be programmed to target specific regions of DNA. During a recent presentation [available here] on this work Ira Deveson described long-read nanopore technology as 'the ideal tool'. He went on to discuss the future potential for nanopore sequencing to 'solve the problem in one step' by reading STRs end-to-end in single long reads.

In the published study the team describe how they achieved accurate molecular characterisation of all known neuropathogenic STRs in a single workflow, as well as DNA methylation, with no additional library preparation or costs. Using nanopore sequencing to target specific regions of interest may also be useful to guide personalised selection of medications.

This research demonstrates the potential for nanopore sequencing in disease characterisation and the study discusses how this could be a powerful approach for STR gene discovery for previously unsolved cases as well.

The full Science Advances publication is available here.


Contact: media@nanoporetech.com

About Oxford Nanopore Technologies

Oxford Nanopore Technologies' goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for real-time, high-performance, accessible and scalable analysis of DNA and RNA. The technology is used in more than 100 countries to understand the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses and whole environments.

Oxford Nanopore Technologies, the Wheel icon, EPI2ME, Flongle, GridION, Metrichor MinION, MinKNOW, PromethION, SmidgION, Ubik and VolTRAX are registered trademarks of Oxford Nanopore Technologies plc in various countries. All other brands and names contained are the property of their respective owners. © 2022 Oxford Nanopore Technologies plc. All rights reserved. Oxford Nanopore Technologies products are not intended for use for health assessment or to diagnose, treat, mitigate, cure, or prevent any disease or condition.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Oxford Nanopore Technologies plc

View source version on accesswire.com:

Back to news